Filtered By:
Procedure: Angioplasty
Countries: China Health

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 136 results found since Jan 2013.

Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
CONCLUSION: As an add-on to standard therapy, MUSKARDIA shows a trend of reduced MACEs in patients with stable CAD and DM. Furthermore, MUSKARDIA may reduce the frequency of all-cause death, hospitalization, and coronary angioplasty in this population, especially in those with uncontrolled DM.TRIAL REGISTRATION: ChiCTR.org.cn, ChiCTR-TRC-12003513.PMID:36752805 | DOI:10.1097/CM9.0000000000002527
Source: Chinese Medical Journal - February 8, 2023 Category: General Medicine Authors: Jingmin Zhou Haiming Shi Fusui Ji Yang Wu Yulan Zhao Jun Qian Junbo Ge Source Type: research

Predictors of parenchymal hemorrhage after endovascular treatment in acute ischemic stroke: data from ANGEL-ACT Registry
Conclusions In Chinese patients with AIS caused by anterior circulation LVO, the risk of PH was positively associated with low admission ASPECTS, serum glucose >7 mmol/L, and NLR, but negatively related to underlying ICAS and intracranial angioplasty/stenting. Trial registration number NCT03370939.
Source: Journal of NeuroInterventional Surgery - December 14, 2022 Category: Neurosurgery Authors: Sun, D., Jia, B., Tong, X., Kan, P., Huo, X., Wang, A., Raynald, , Ma, G., Ma, N., Gao, F., Mo, D., Song, L., Sun, X., Liu, L., Deng, Y., Li, X., Wang, B., Luo, G., Wang, Y., Ren, Z., Miao, Z., on behalf of ANGEL-ACT study group, Miao, Gui, Peng, Wu, Zha Tags: Ischemic stroke Source Type: research

The CASSISS Randomized Clinical Trial
Stroke. 2022 Nov 11. doi: 10.1161/STROKEAHA.122.041096. Online ahead of print.ABSTRACTThe CASSISS trial (China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis), recently published in JAMA, is the most recent of several randomized controlled trials that have failed to show a benefit of percutaneous angioplasty and stenting over medical therapy for the prevention of stroke due to intracranial atherosclerotic stenosis. Current practice guidelines recommended that percutaneous angioplasty and stenting should not be performed routinely as a treatment for stroke prevention in patients with intracranial at...
Source: Atherosclerosis - November 11, 2022 Category: Cardiology Authors: Tanya N Turan Marios-Nikos Psychogios Source Type: research

Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research

A rare cause of abdominal pain managed unconventionally: acute renal infarction caused by atrial fibrillation: a case report
ConclusionsAcute renal infarction from thromboembolism is a rare but serious complication of arterial fibrillation. More efficient and different options for intervention methods will benefit the treatment of this disease. Here, we report a combination therapeutic method that has not been used in acute renal infarction associated with arterial fibrillation, and which restored renal perfusion and prevented long-term kidney injury.
Source: Journal of Medical Case Reports - October 19, 2022 Category: General Medicine Source Type: research

Stenting Hits Another Wall in Intracranial Stenosis Stroke
(MedPage Today) -- Intracranial angioplasty again failed for less severe intracranial atherosclerotic stenosis (ICAS) strokes in a Chinese trial. However, a separate analysis did leave a glimmer of hope that IV antiplatelet therapy prior to thrombectomy...
Source: MedPage Today Cardiovascular - August 9, 2022 Category: Cardiology Source Type: news

DES reduce the risk of ISR in patients with ICAS compared to BMS
Dr. Snipe Clinical question: In patients with symptomatic high-grade intracranial atherosclerotic stenosis (ICAS), does the use of a drug-eluting stent (DES) reduce the incidence of in-stent restenosis (ISR) and stroke recurrence compared to using a bare-metal stent (BMS)? Background: ICAS is a common cause of stroke in North America (accounting for 8-10% of strokes) and is even more common in Asia (accounting for 30-50% of strokes). In previous trials, aggressive medical management was found to be the superior first-line treatment, but intracranial stenting is growing in popularity and safety. DES is known to reduce ISR ...
Source: The Hospitalist - August 1, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: CAD & Atherosclerosis Critical Care In the Literature Source Type: research

Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis
CONCLUSIONS: This Cochrane Review provides low- to moderate-certainty evidence indicating that there are no significant differences in either short- or long-term risks of stroke, death, or TIA between people with symptomatic vertebral artery stenosis treated with ET plus MT and those treated with MT alone.PMID:35579383 | DOI:10.1002/14651858.CD013692.pub2
Source: Cochrane Database of Systematic Reviews - May 17, 2022 Category: General Medicine Authors: Ran Xu Xiao Zhang Sihua Liu Xue Wang Wenjiao Wang Kun Yang Tao Wang Adam A Dmytriw Xuesong Bai Yan Ma Liqun Jiao Bin Yang Source Type: research

Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
This study aimed to evaluate the efficacy and safety of the early initiation of evolocumab in Chinese patients with ACS undergoing PCI.METHODS: This retrospective cohort study involved 1564 consecutive patients who had been hospitalized with ACS and underwent PCI, and who had elevated LDL-C levels (≥1.8 mmol/L after receiving high-intensity statin therapy for ≥4 weeks; ≥2.3 mmol/L after receiving low- or moderate-intensity statin; or ≥3.2 mmol/L without statin therapy). Patients who received evolocumab (initiated in-hospital and after 18 months) were included in the evolocumab group (n = 414), and all other patient...
Source: Clinical Therapeutics - May 17, 2022 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Bin Zhang Zheng Chen Yongjie Wei Penglei Chen Chao Chang Guizhi Liu Kui Chen Jiandong Ding Zhengming Jiang Source Type: research